User Visiting Statistics

Tumor Immune Syngeneic MOuse (TISMO) is a database specifically designed for hosting, visualizing, and analyzing an extensive collection of syngeneic mouse model data. We uniformly processed raw sequencing data for 1,518 mouse samples, covering 68 cell lines and 19 cancer types, to generate gene expression and immune cell infiltration profiles, of which 832 were from immune checkpoint blockade (ICB) studies. In addition, TISMO hosts 605 in vitro samples of which 195 were cytokine treated. Sample metadata, including cancer type, cell line, mouse strain, transplantation site, ICB treatment, and response status were manually curated. TISMO provides interactive interfaces for users to explore gene expression and immune infiltration, and allows systematic comparisons between different model characteristics, and treatment and response groups.

Get started by exploring:
Explore the TISMO overview module that summarizes model and treatment information. The metadata module stores the phenotypic information for all collected samples.
Select a gene to compare its expression level in either in vivo or in vitro samples across treatment and response conditions.
Select a pathway to compare its expression level in either in vivo or in vitro samples across treatment and response conditions.
Select an immune infiltrate to compare its level in either ICB treated or treatment-naive samples across models.

TISMO Database Overview:

Tutorial:


Cite us!

Zexian Zeng*#, Cheryl J Wong*, Lin Yang*, Nofal Ouardaoui, Dian Li, Wubing Zhang, Shengqing Gu, Yi Zhang, Yang Liu, Xiaoqing Wang, Jingxin Fu, Liye Zhou, Boning Zhang, Sarah Kim, Kathleen B Yates, Myles Brown, Gordon J Freeman, Ravindra Uppaluri, Robert Manguso, X Shirley Liu#. TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response. Nucleic Acids Research 2021 [DOI] [PubMed]

Contact:

Zexian Zeng: zzeng@ds.dfci.harvard.edu
X Shirley Liu: xsliu@ds.dfci.harvard.edu


User Visiting Statistics

TISMO | © X Shirley Liu Lab 2021 | Dana Farber Cancer Institute

An overview of the syngeneic mouse model data in the TISMO database. TISMO contains 605 in vitro RNA-seq samples from 49 syngeneic cancer cell lines across 23 cancer types, of which 195 underwent cytokine treatment. TISMO also includes 1,518 in vivo RNA-seq samples from 68 syngeneic mouse tumor models across 19 cancer types, of which 832 were from immune checkpoint blockade (ICB) studies. The ‘ICB Treatment’ tab summarizes tumor samples treated with immune-checkpoint blockade such as anti-PD1, anti-PDL1, anti-PDL2, antiCTLA4, and anti-CTLA4 + anti-PD1/L1 combinations. The ‘Cytokine Treatment’ tab summarizes in vitro tumor lines treated with cytokines such as interferon γ (IFNγ), IFNβ, tumor necrosis factor alpha (TNFα) and transforming growth factor (TNFβ). The ‘Baseline’ tab summarizes in vivo and in vitro samples used as study controls (e.g. untreated, isotype or vehicle treated).

We have collected available survival information from published studies. Survival information is available in 32% of ICB-related samples and 24% of total in vivo tumor samples in TISMO.


Compare gene expression levels across different tumor models and ICB treatments, between pre- and post-ICB treatment and responders and non-responders.

ICB treatments included in this module: anti-PD1, anti-PDL1, anti-PDL2, and anti-CTLA4.

The differences between groups are statistically evaluated by Wald test using DESeq2 (*FDR ≤ 0.05, **FDR ≤ 0.01, ***FDR ≤ 0.001), and the comparison results are summarized in boxplots.

Tumor models included are: Mammary cancer: 4T1, E0771, EMT6, T11, KPB25L, p53-2225L, p53-2336R; Colorectal carcinoma: CT26, MC38; Gastric adenocarcinoma: YTN16; Head and neck squamous cell carcinoma: MOC22; Hepatocellular carcinoma: BNL-MEA; Lung carcinoma: LLC; Melanoma: B16, YUMM1.7, D3UV2, D4M.3A.3; Sarcoma: 402230.


Compare gene expression levels across cell-lines between pre- and post-cytokine treated samples.

Cytokine treatments included in this module: IFNγ, IFNβ, TNFα, and TGFb1.

The differences between groups are statistically evaluated by Wald test using DESeq2 (*FDR ≤ 0.05, **FDR ≤ 0.01, ***FDR ≤ 0.001), and the comparison results are summarized in boxplots.

Cell lines included are: Mammary cancer: 4T1, EMT6, E0771; Colorectal carcinoma: CT26, MC38; Lung carcinoma: LLC; Head and neck squamous cell carcinoma: MOC1; Melanoma: B16; Pancreatic ductal adenocarcinoma: KPC, Panc02; Renal adenocarcinoma: Renca;


Compare pathways across different tumor models and ICB-treatments, between pre- and post-ICB treatment and responders and non-responders.

ICB treatments included in this module: anti-PD1, anti-PDL1, anti-PDL2, and anti-CTLA4.

The differences between groups are statistically evaluated by the Wilcox test (*p-value ≤ 0.05, **p-value ≤ 0.01, ***p-value ≤ 0.001), and the comparison results are summarized in boxplots.

Tumor models included are: Mammary cancer: 4T1, E0771, EMT6, T11, KPB25L, p53-2225L, p53-2336R; Colorectal carcinoma: CT26, MC38; Gastric adenocarcinoma: YTN16; Head and neck squamous cell carcinoma: MOC22; Hepatocellular carcinoma: BNL-MEA; Lung carcinoma: LLC; Melanoma: B16, YUMM1.7, D3UV2, D4M.3A.3; Sarcoma: 402230.